Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4709 USD | +6.11% | -12.52% | -48.45% |
Feb. 07 | Transcript : 23andMe Holding Co., Q3 2024 Earnings Call, Feb 07, 2024 | |
Feb. 07 | Earnings Flash (ME) 23ANDME Reports Q3 Revenue $44.7M, vs. Street Est of $56.3M | MT |
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-48.45% | 227M | - | - | |
-0.26% | 4.06B | B- | ||
+28.93% | 3.3B | C+ | ||
+1.23% | 2.76B | - | ||
-23.30% | 2.01B | B- | ||
-10.07% | 1.86B | C- | ||
-16.63% | 1.72B | C+ | ||
-16.57% | 1.63B | A- | ||
-11.04% | 1.06B | - | - | |
-5.38% | 981M | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock 23andMe Holding Co. - Nasdaq
- Ratings 23andMe Holding Co.